Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.19
Bid: 2.21
Ask: 2.30
Change: -0.115 (-4.99%)
Spread: 0.09 (4.072%)
Open: 2.19
High: 2.19
Low: 2.19
Prev. Close: 2.305
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Shareholder Meetings Calendar - Next 7 Days

Thu, 11th Jun 2020 16:17

Friday 12 June
Katoro Gold
Informa
Bakkavor
Capital Drilling
Monday 15 June
IQ-AI
Mirriad Advertising
Tuesday 16 June
Marshall Motor
Clearstar
Epwin Group
Coca-Cola HBC
Science Group
Altus Strategies
Arbuthnot Banking
Evraz
Andrews Sykes Group
FDM Group
Wednesday 17 June
Amigo Holdings (re board removal)
RTC Group 
Wentworth Resources 
STM Group
Salt Lake Potash
Domino's Pizza Group
Pelatro 
UK Oil & Gas
G4S
Thursday 18 June
Ted Baker (re share placing)
IP Group
Horizon Discovery
Ten Entertainment
Shield Therapeutics
Tremor International
Jadestone Energy
Vietnam Enterprise
Intelligent Ultrasound Group
Block Energy
RBG Holdings
Impact Healthcare
Michelmersh
Immupharma
 
Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
28 Jan 2013 16:06

ImmuPharma non-exec reduces stake

Dr Ajay Agrawal, Non-Executive Director of ImmuPharma, sold a stack of shares in the AIM-listed drug company, it was announced Monday. Agrawal traded in 62,169 shares at 57p a time on January 24th, pocketing £35,436 before tax. The deal was announced the same day the group said its key scientific

Read more
28 Jan 2013 12:58

Immupharma reports success of partner's latest Lupus drug trial

Drug development firm ImmuPharma said Monday that its key scientific collaboration partner and the inventor of ImmuPharma's lead compound, Lupuzor, has confirmed the effectiveness of a product known as Lupuzor peptide P140. Partner CNRS released a statement saying that in a clinical trial involvin

Read more
27 Mar 2012 10:27

ImmuPharma's losses grow in 2011

Drug development firm ImmuPharma increased its losses during 2011 but managed to regain the rights to its most important compound. The loss for the year was £3.35m, against the prior year's loss of £1.98m. The loss per share increased from 2.44p in 2010 to 4.12p in 2011. ImmuPharma's lead product

Read more
24 Jan 2012 16:32

SABMiller exec buys a round

The Managing Director of SABMiller's African division bought a round of shares just one day before the drinks giant announced it has signed a definitive transaction agreement with Anadolu Group and Anadolu Efes. The agreement allows the firm to form a strategic alliance between the firm's divisions

Read more
5 Apr 2011 12:01

Immupharma posts wider losses

Drug discovery group Immupharma fell into losses in the year to 31 December, but pointed to progress with its ongoing trials. Pre-tax losses totalled £2m for the year, against a profit of £9.1m the previous year. Revenues fell to just £325,000 from £22.05m. "Early results of our cancer programme

Read more
23 Jun 2010 16:00

UK SMALLCAP ROUNDUP: Mariana Resources Raises GB6.75 Million

Dow Jones smallcap news is on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps MARIANA RESOURCES LTD. (MARL.LN), a gold, silver and copper explorer, Wednesday said it agreed to raise GBP6.75 million in a share sale to fund drilling at i

Read more
23 Jun 2010 07:28

Immupharma Partner Cephalon Starts Phase 2b Trials Recruitment

LONDON (Dow Jones)--Immupharma PLC (IMM.LN), a specialist drug discovery and development company, said Wednesday that Cephalon Inc. (CEPH), its license partner for IPP-201101 (Rigerimod; Lupuzor) has started the recruitment of lupus patients for a Phase IIb trial in the U.S. MAIN FACTS: -Stu

Read more
19 Nov 2009 11:01

Small caps round-up: White Young Green, Beowulf, Angel Biotech...

Engineering consultant White Young Green has traded in line with expectations since the end of June, with conditions varying across its markets. "There remains a lack of confidence and liquidity in many areas in which we trade, but there are also some encouraging signs in respect of opportunities

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.